Dr David Melnick is an infectious diseases clinician who has spent more than 25 years in anti-infective drug development. Throughout his career, Dr Melnick has helped to address antimicrobial resistance with novel antibiotics and dosing strategies, including leading successful antibiotic development programs for drugs including meropenem, ceftaroline, and ceftazidime-avibactam.
Dr Melnick is an independent consultant advising biotechnology companies on the design and delivery of drug development programs. Throughout his career he has held senior leadership positions including Chief Medical Officer at Spero Therapeutics, and VP of Clinical Development at AstraZeneca and Allergan.
He received his medical degree from Columbia University and completed his Residency in Internal Medicine at The New York Hospital-Cornell Medical Center. Following a Fellowship in Infectious Disease at Yale University, he held faculty positions at the Boston University School of Medicine and NIAID. Dr Melnick is certified by the American Board of Surgery and is a Fellow of the American College of Surgeons.